@article{7d28be66c3f54ceabd5ec8b08961dce6,
title = "A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis",
author = "{On behalf of the Dupilumab Italian National Access Program (Dup-INAP group)} and Fargnoli, {M. C.} and M. Esposito and S. Ferrucci and G. Girolomoni and A. Offidani and A. Patrizi and K. Peris and A. Costanzo and G. Malara and G. Pellacani and M. Romanelli and P. Amerio and A. Cristaudo and Flori, {M. L.} and A. Motolese and P. Betto and C. Patruno and P. Pigatto and C. Peccianti and G. Stinco and I. Zalaudek and L. Bianchi and V. Boccaletti and Cannavo, {S. P.} and F. Cusano and S. Lembo and R. Mozzillo and R. Gallo and C. Potenza and F. Rongioletti and R. Tiberio and T. Grieco and G. Micali and S. Persechino and M. Pettinato and S. Pucci and L. Stingeni and C. Caruso and G. Argenziano",
year = "2022",
doi = "10.1080/09546634.2020.1773379",
language = "English",
volume = "33",
pages = "1146--1149",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "2",
}